A phase I/II study ReFocus (NCT04526106) was conducted to evaluate RLY-4008 in patients (n = 38) with cholangiocarcinoma harboring FGFR2 fusions/rearrangements who did not receive prior FGFR inhibitors. This evidence concerns the gene FGFR2 and cholangiocarcinoma.